This Biotech Holds Up In Buy Zone Despite Falling Market

Core Viewpoint - United Therapeutics is demonstrating resilience in the biotech sector, maintaining its position in a buy zone despite a broader market decline, making it a stock to watch this week [1]. Group 1: Stock Performance - After a period of consolidation, United Therapeutics' stock broke out from a flat base on February 25, surpassing a buy point of 519.99 following strong earnings that increased the stock by over 13% [2]. - The stock's relative strength line has shown a significant upward trend, with a Relative Strength Rating of 92, indicating it has outperformed 92% of companies in the database over the past year [3]. - The stock holds a Composite Rating of 97 and an Accumulation/Distribution Rating of A-, reflecting robust institutional support [3]. Group 2: Financial Performance - United Therapeutics reported earnings of $7.70 per share in the fourth quarter, marking a 24% increase, with sales reaching $790.2 million, a 7% growth [5]. - Revenue from the drug Tyvaso grew by 12% to $464.3 million in the fourth quarter of 2025, compared to $415.9 million in the same quarter of 2024 [6]. Group 3: Future Growth Potential - The CEO of United Therapeutics, Martine Rothblatt, highlighted promising results from clinical programs that could lead to significant growth, with upcoming data from the Advance Outcomes and Teton-1 programs expected to unlock new treatment options [7].